CAMCEVI
Asset
Sustained GnRH receptor agonism suppresses gonadotropin release and testosterone production.
- Stage
- Approved
- Modality
- Peptide
- Target
- GNRHR
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Advanced prostate cancer
Approved, prnewswire.com, 12 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners2
- Evidence for its targets1
- Competitors1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.